Joint

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, MRI, INN, Risk, Contraindication, AZA, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Contraindication, AZA, Tissue, Heart, Cancer, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, Psoriasis, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Blood, Safety, Heart failure, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, C-reactive protein, MRI, INN, Risk, Polyarthritis, Lung, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Bacteria, Anatomy, IIA, Skin, DSM-IV codes, ATC, Joint, Pain, Psoriatic arthritis, Itch, Bleeding, Disease, Ageing, Nonsteroidal anti-inflammatory drug, Human, Safety, CRP, Rheumatoid arthritis, Sepsis, Magnetic resonance imaging, Patient, Medical Subject Headings, International, Arthritis, Language, Blood, Select, Juvenile idiopathic arthritis, Methotrexate, Common, TNF, PUVA, Swelling, European Medicines Agency, Spine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Contraindication, INN, Risk, AZA, Nausea, Heart, Inflammation, Disease-modifying antirheumatic drug, Infection, Diagnosis, Risk management, Anatomy, Ulcer, IIA, CHMP, Skin, Sinusitis, ATC, Joint, Pain, Psoriatic arthritis, Drainage, European, Disease, Ageing, Human, Safety, Heart failure, Rheumatoid arthritis, Medical Subject Headings, Agency, European Commission, Immune system, Ulcerative colitis, ACR, International, Arthritis, Language, Blood, Ciclosporin, Viral, Tuberculosis, Select, Patient, Medicine, Methotrexate, Azathioprine, Common, Tumor necrosis factor, Allergy, PUVA, Glycine mollis, Headache, Abdominal pain, Ankylosing spondylitis, Spine, Chronic pain, Committee, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout

Retrieved on: 
Tuesday, January 2, 2024
Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Food, Inflammatory arthritis, Probability, IND, Extremities, Joint, Gout, URAT1, Uric acid, Disease, Swelling, Animal, DSM-IV codes, Safety, Pharmaceutical industry

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 clinical trial of ABP-745, an anti-inflammatory oral small molecule drug, for the treatment of acute gout.

Key Points: 
  • Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 clinical trial of ABP-745, an anti-inflammatory oral small molecule drug, for the treatment of acute gout.
  • Atom also has submitted an IND application for a Phase 1 clinical of ABP-745 in China.
  • Dr. William Dongfang Shi, Founder, Chairman and CEO of Atom Biosciences, said, “The IND clearance of ABP-745 is important progress in the anti-inflammatory research field of Atom Bioscience’s clinical development.
  • We expect to begin the Phase 1 trial for acute gout in the U.S. soon.

Indian Finance Minister Smt Nirmala Sitharaman to inaugurate DATE in New Delhi

Retrieved on: 
Wednesday, November 22, 2023
Dubai International Financial Centre, Digital India Corporation, Confederation, STPI, Policy, Sanjiv Bajaj, Fintech, Ecosystem, Federation, FICCI, Government, Volvo, MD, Commerce, Name, YOY, Confederation of Indian Industry, Electronics, Joint, DIC, SCCI, Economic Advisory Council

India's digital landscape and swift adoption of groundbreaking, next-generation solutions are fundamentally reshaping its economic landscape.

Key Points: 
  • India's digital landscape and swift adoption of groundbreaking, next-generation solutions are fundamentally reshaping its economic landscape.
  • Shri Yaduveer Krishnadatta Chamaraja Wadiyar, Chairperson of Cyberverse Foundation, a Strategic Partner of DATE, expressed, "With the support & participation of government leaders & policy makers like Finance Minister Smt.
  • Nirmala Sitharaman, Minister of State Shri Rajeev Chandrasekhar, Shri Sanjeev Sanyal, Shri Tejasvi Surya and more, DATE plays a pivotal role in fostering government-industry relations, propelling India towards a digitally empowered future."
  • Mohammed Saleem, Founder and Chairman of Trescon, added, "DATE signifies our dedication to catalyze India's digital revolution.

Acrometa Subsidiary Signs Two MOUs to Develop Co-Working Laboratory Space Business in China

Retrieved on: 
Friday, November 17, 2023
Ecosystem, Partnership, Health, Biotechnology, Research, Municipal solid waste, Executive, Joint, MOU, Republic, Certification, SME, LSI, Growth, Investment, Fine chemical

- New strategic partnership reflects continued efforts to explore international expansion opportunities for the Group's scalable and replicable co-working laboratory space business.

Key Points: 
  • - New strategic partnership reflects continued efforts to explore international expansion opportunities for the Group's scalable and replicable co-working laboratory space business.
  • Fenglin Group will promote the co-working laboratory space with a focus on overseas biomedical science startups and SMEs planning to develop their business in China.
  • On its part, LSI will use its existing business networks to recommend to Fenglin Group, Singapore and other overseas biomedical sciences companies that intend to have a business foothold in China and need co-working laboratory space.
  • The business model for the Group's co-working laboratory space business is scalable and replicable and therefore eminently suitable for international expansion."

EQS-News: Turkey Could Host Gulf Countries in the Fintech Sector

Retrieved on: 
Saturday, December 30, 2023
Fintech, Zawar Farid, Joint, Century, Investment, Transport, ARAB, Drug

During President Erdoğan's visits to the UAE and Qatar, the main agenda included the latest situation in Gaza, along with regional and global developments, and collaborations between countries.

Key Points: 
  • During President Erdoğan's visits to the UAE and Qatar, the main agenda included the latest situation in Gaza, along with regional and global developments, and collaborations between countries.
  • For instance, Turkey could become a center for fintech in the Gulf countries," he said.
  • As voluntary ambassadors of our country, we invite all investors to join us in winning together with Turkey.
  • Turkey, attracting foreign  investors in various fields from industry to finance, and from energy to transportation, will continue to grow with these investments," he stated.

PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH COVETRUS NORTH AMERICA, LLC

Retrieved on: 
Friday, December 22, 2023
Marketing, Osteoarthritis, Animal, Joint, Veterinarian, Patient, Therapy, Arthralgia

MINNEAPOLIS, Dec. 22, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Covetrus North America, LLC (“Covetrus”).

Key Points: 
  • MINNEAPOLIS, Dec. 22, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Covetrus North America, LLC (“Covetrus”).
  • Covetrus will inventory, market and promote PetVivo’s veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout the United States.
  • "We are incredibly pleased to add Covetrus to our current distribution network to distribute our signature product, Spryng with OsteoCushion technology.
  • For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact [email protected] or visit https://petvivo.com/ and https://sprynghealth.com/ .

PetVivo Holdings, Inc. Achieves Distribution Milestone Surpassing 4500 Syringes of Spryng™ in 2023

Retrieved on: 
Thursday, December 21, 2023
Ethos, Conference, Syringe, Osteoarthritis, Trial of the century, Animal, Joint, Veterinarian, Therapy, Arthralgia, Pharmaceutical industry

MINNEAPOLIS, MN, US, Dec. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – surpassing 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year.

Key Points: 
  • MINNEAPOLIS, MN, US, Dec. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – surpassing 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year.
  • The distribution of syringes of Spryng is an increase in excess of sixty percent from the previous year.
  • SPRYNG™ with OsteoCushion™ Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
  • For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact [email protected] or visit https://petvivo.com/ and https://sprynghealth.com/ .